A
Alcista
Alcista · 25%ERAS
$1.99
Precio del escenario
$13.390
-1.332 (-9.95%)Al cierre
Loading chart…
- Máximo
- 14.870
- Apertura
- 14.870
- Precio medio ponderado por volumen
- 13.84
- Volumen
- 7.09M
- Capitalización
- 630.21M
- Mínimo
- 13.265
- Importe
- 98.13M
- EV/EBITDA, TTM
- 0.00
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Análisis de IA of Erasca Inc (ERAS)
ComprarErasca Inc is a good buy right now due to its current price of $16.03, which is significantly lower than analyst price targets, including $33 from JPMorgan and $22 from H.C. Wainwright. Additionally, the stock has shown a remarkable year-to-date change of +346.52%, indicating strong momentum. However, the main risk is the high insider selling activity, which increased by 336.23% over the last month, suggesting potential concerns among insiders about the company's future performance.
Métricas de valoración
El PER previsto actual de Erasca Inc (ERAS) es 0.00, frente a su media de 5 años de -4.57.
Escenarios de precio de Alphio AI para ERAS
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con ERAS en cartera
Cronología de eventos
Noticias
7.010-15NewsfilterInvestigation into Aardvark Therapeutics Shareholder Claims
7.010-12NewsfilterAmerican Express Faces Compliance Investigation
- 7.009-10Newsfilter
Investigation into Aardvark Therapeutics Shareholder Claims
- 8.508-24Newsfilter
Erasca Receives FDA Fast Track Designation for ERAS-0015
- 7.008-14Newsfilter
ARS Pharmaceuticals and Others Under Shareholder Investigation
Preguntas frecuentes sobre ERAS, respondidas por Alphio AI
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Erasca Inc is a good buy right now due to its current price of $16.03, which is significantly lower than analyst price targets, including $33 from JPMorgan and $22 from H.C. Wainwright. Additionally, the stock has shown a remarkable year-to-date change of +346.52%, indicating strong momentum. However, the main risk is the high insider selling activity, which increased by 336.23% over the last month, suggesting potential concerns among insiders about the company's future performance.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.